EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Summary - MDSpire

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

Objective:

To analyze the long-term health outcomes of testicular cancer survivors treated with different chemotherapy regimens, specifically comparing EPx4 and BEPx3.

Key Findings:
  • Patients treated with EPx4 had 1.55 times the odds of renal impairment compared to BEPx3, and BEPx4 was linked to higher odds of Raynaud phenomenon compared to EPx4.
Interpretation:

Long-term survivors of testicular cancer treated with EPx4 face increased risks of renal, nerve, and hearing complications compared to those treated with BEPx3, highlighting the need for careful long-term health management.

Limitations:
  • text
Conclusion:

This study highlights the comparable long-term CBM scores between EPx4 and BEPx3, but significant differences in cisplatin-related toxicities, emphasizing the need for careful monitoring of long-term health outcomes, particularly renal and neurological health.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

Can Lower Music Levels Preserve Workout Intensity?

Despite preserved exertion perceptions, researchers report limited hearing protection use in group fitness classes.

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.